down arrow

Galectin Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US3632252025
USD
6.30
0.84 (15.38%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

5.766.52

52 Week

0.736.55
Valuation
Technical
Day's Volume

CASH

181.93 k

Shareholding (Mar 2025)

FII

0.79%

Held by 14 FIIs

DII

92.99%

Held by 7 DIIs

Promoter

0.00%

How big is Galectin Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Galectin Therapeutics, Inc. has a market capitalization of 151.27 million and reported net sales of 0.00 million with a net profit of -45.19 million over the last four quarters. The company's shareholder's funds were -103.07 million, with total assets of 17.50 million as of Dec 24.

Market Cap: As of Jun 18, Galectin Therapeutics, Inc. has a market capitalization of 151.27 million, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Galectin Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -45.19 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds were -103.07 million, and total assets amounted to 17.50 million.

Read More

What does Galectin Therapeutics, Inc. do?

22-Jun-2025

Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for fibrotic diseases and cancer, with a market cap of approximately $151.27 million. The company reported a net loss of $10 million in its most recent quarter.

Overview:<BR>Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development for fibrotic disease and cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 151.27 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.90<BR>Return on Equity: 41.53%<BR>Price to Book: -1.35<BR><BR>Contact Details:<BR>Address: 4960 Peachtree Industrial Blvd Ste 240, BERKELEY LAKE GA: 30071-1580<BR>Tel: 1 678 6203186<BR>Website: http://galectintherapeutics.com/

Read More

Who are in the management team of Galectin Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Galectin Therapeutics, Inc. includes Richard Uihlein (Independent Chairman), Joel Lewis (CEO), Adam Allgood (Executive Director of Clinical Development), and several directors including James Czirr, Harold Shlevin, Gilbert Amelio, and Kary Eldred. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Galectin Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Richard Uihlein, Independent Chairman of the Board<BR>- Mr. Joel Lewis, President, Chief Executive Officer, Director<BR>- Dr. Adam Allgood, Executive Director of Clinical Development<BR>- Mr. James Czirr, Director<BR>- Dr. Harold Shlevin, Director<BR>- Dr. Gilbert Amelio, Independent Director<BR>- Mr. Kary Eldred, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is Galectin Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 29, 2025, Galectin Therapeutics, Inc. shows a bullish trend with strong technical indicators, outperforming the S&P 500 significantly year-to-date with a return of 259.69% compared to 12.22%.

As of 29 August 2025, the technical trend for Galectin Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, while the Bollinger Bands show a bullish signal monthly and mildly bullish weekly. Moving averages are bullish on the daily chart, and the KST is bullish on both weekly and monthly time frames. Although the Dow Theory indicates a mildly bullish stance weekly and monthly, the overall technical picture remains positive.<BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 259.69% compared to the S&P 500's 12.22%. Over the past year, the stock has returned 71.22% against the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 299 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.91

stock-summary
Return on Equity

34.62%

stock-summary
Price to Book

-2.55

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-8 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
40.31%
0%
40.31%
6 Months
388.37%
0%
388.37%
1 Year
142.31%
0%
142.31%
2 Years
215.0%
0%
215.0%
3 Years
416.39%
0%
416.39%
4 Years
176.32%
0%
176.32%
5 Years
129.93%
0%
129.93%

Galectin Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Galectin Therapeutics, Inc. technically bullish or bearish?

As of 29 August 2025, the technical trend for Galectin Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, while the Bollinger Bands show a bullish signal monthly and mildly bullish weekly. Moving averages are bullish on the daily chart, and the KST is bullish on both weekly and monthly time frames. Although the Dow Theory indicates a mildly bullish stance weekly and monthly, the overall technical picture remains positive. In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 259.69% compared to the S&P 500's 12.22%. Over the past year, the stock has returned 71.22% against the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-39.32%
EBIT to Interest (avg)
-20.86
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
19.67%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.74
EV to EBIT
-4.53
EV to EBITDA
-4.53
EV to Capital Employed
-15.73
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 10 Schemes (6.22%)

Foreign Institutions

Held by 14 Foreign Institutions (0.79%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 39.52% vs -36.26% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.60",
          "val2": "-11.30",
          "chgp": "59.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.80",
          "val2": "1.30",
          "chgp": "38.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.10",
          "val2": "0.10",
          "chgp": "-1,200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.50",
          "val2": "-12.40",
          "chgp": "39.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -14.36% vs -5.93% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-42.40",
          "val2": "-38.00",
          "chgp": "-11.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "5.50",
          "val2": "2.80",
          "chgp": "96.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.60",
          "val2": "-0.40",
          "chgp": "250.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-47.00",
          "val2": "-41.10",
          "chgp": "-14.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.60
-11.30
59.29%
Interest
1.80
1.30
38.46%
Exceptional Items
-1.10
0.10
-1,200.00%
Consolidate Net Profit
-7.50
-12.40
39.52%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 39.52% vs -36.26% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-42.40
-38.00
-11.58%
Interest
5.50
2.80
96.43%
Exceptional Items
0.60
-0.40
250.00%
Consolidate Net Profit
-47.00
-41.10
-14.36%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -14.36% vs -5.93% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Galectin Therapeutics, Inc. stock-summary
stock-summary
Galectin Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
Company Coordinates stock-summary
Company Details
4960 Peachtree Industrial Blvd Ste 240 , BERKELEY LAKE GA : 30071-1580
stock-summary
Tel: 1 678 6203186
stock-summary
http://galectintherapeutics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."